The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML)

Tiong, Ing Soo, Dillon, Richard, Ivey, Adam, Kok, Chung Hoow, Kuzich, James Anton, Thiagarajah, Nisha, Bajel, Ashish, Potter, Nicola, Smith, Matthew, Hemmaway, Claire, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Gilkes, Amanda, Russell, Nigel H. and Wei, Andrew H. 2020. The natural history of NPM1MUT Measurable Residual Disease (MRD) positivity after completion of chemotherapy in Acute Myeloid Leukemia (AML). Presented at: 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020), Virtual, 5-8 December 2020. Blood. , vol.136 (Supple) American Society of Hematology, pp. 25-27. 10.1182/blood-2020-140296

Full text not available from this repository.

Abstract

Molecular MRD assays targeting NPM1 mutant (mut) transcripts have an established role for monitoring treatment efficacy in patients with NPM1mut AML. Approximately 25% of NPM1mut patients show persistent MRD level in the bone marrow (BM) at the end of treatment (EOT), which is associated with a higher risk of relapse (Ivey, NEJM 2016; Kronke, JCO 2011). Molecular persistence at low copy number (MP-LCN) is defined by the European LeukemiaNet (ELN) as MRD positivity in patients in morphological complete remission (CR) with <1000-2000 transcripts per 105ABL and a relative increase of <1 log between any two positive samples collected after EOT (Schuurhuis, Blood 2018). The UK NCRI working group recently reported the impact of NPM1mut MRD burden and FLT3-ITD status on risk of relapse after allogeneic stem cell transplantation (Dillon, Blood 2020), however the clinical relevance of NPM1mut MP-LCN in patients who are not transplanted is unknown. We aimed to characterize the natural history of persistent NPM1mut MRD after chemotherapy and to identify factors associated with subsequent disease progression.

Item Type:	Conference or Workshop Item (Paper)
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	American Society of Hematology
ISSN:	1528-0020
Last Modified:	10 Nov 2022 10:22
URI:	https://orca.cardiff.ac.uk/id/eprint/146613

Actions (repository staff only)

Edit Item